Key Highlights
Medicine · Gastroenterology, Hepatology
A correction to the LIR!C trial’s 10-year follow-up data has refined the comparative effectiveness of ileocaecal resection versus infliximab for ileal Crohn’s disease. The correction, stemming from a coding error for one patient in the surgical group, adjusts the 10-year clinical remission rate for ileocaecal resection to 35.8% and the hazard ratio for remission between groups to 0.81 (95% CI 0.53–1.23, p=0.31). For a medical student focused on evidence-based practice, this correction is a critical lesson in data integrity and emphasizes that the long-term clinical outcomes between these two key interventions remain statistically indistinguishable.
Novelty: 40%
Rigor: 98%
Significance: 85%
Validity: 99%
Clarity: 90%
Update Your Briefing Preferences
Stay curious. Stay informed —
Science Briefing
Your briefing is personalized based on your selected fields, keywords, and research interests.
